3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
145
Carcinoma, Intraductal, Noninfiltrating
12
Breast Carcinoma In Situ
10
Neoplasm Metastasis
9
Breast Neoplasms, Male
9
Neoplasms
5
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Inflammatory Breast Neoplasms
3
Gliosarcoma
3
Glioma
3
Glioblastoma
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Central Nervous System Neoplasms
3
Carcinoma, Ductal, Breast
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Oligodendroglioma
2
Multiple Endocrine Neoplasia Type 1
2
Liver Neoplasms
2
Hot Flashes
2
Glioma, Subependymal
2
Fibroadenoma
2
Ependymoma
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Astrocytoma
2
Thyroid Neoplasms
1
Interventions
Insulin Glargine
2
Insulin
2
Alpelisib
2
ziprasidone
1
relacorilant
1
pembrolizumab
1
exemestane
1
Vildagliptin
1
Tamoxifen
1
Olanzapine
1
Metformin
1
Letrozole
1
Insulin Lispro
1
Injections
1
Fulvestrant
1
DNA, Ribosomal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hyperglycemia
×
Tamoxifen
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled